You are here

Article Text

Article menu
Download PDFPDF
Short report
Soluble CD30 as a prognostic factor for outcome following renal transplantation
  1. R E Platt1,
  2. K S T Wu2,
  3. K Poole1,
  4. C G Newstead2,
  5. B Clark1
  1. 1
    Transplant Immunology, St James’s University Hospital, Leeds, UK
  2. 2
    Department of Renal Medicine, St James’s University Hospital, Leeds, UK
  1. Miss R E Platt, Transplant Immunology, Level 09, Gledhow Wing, St James’s University Hospital, Leeds LS9 7TF, UK; ruthieplatt{at}hotmail.com

Abstract

Aims: To determine whether measurement of soluble CD30 (sCD30) levels predicts for early rejection in a cohort of first deceased kidney transplant recipients.

Methods: Pre-transplant serum samples were analysed for sCD30 levels using a commercial ELISA kit (Biotest). A 100 U/ml cut-off for “high sCD30” was applied. Clinical outcome parameters were biopsy-proven rejection episodes, creatinine levels and glomerular filtration rate.

Results: In the cohort of patients who experienced at least one episode of rejection in the first 6 months post-transplant, levels of pre-transplant sCD30 were significantly higher than in those who did not experience rejection. Despite this association, the occurrence of a high sCD30 level did not predict for rejection on an individual basis.

Conclusions: The prognostic value of pre-transplant sCD30 testing is diminished by the large number of patients with high sCD30 levels who do not develop rejection. Although this limits the utility of the test in informing clinical management of individual patients, a high pre-transplant sCD30 level should still be considered a risk factor for poorer outcome.

https://doi.org/10.1136/jcp.2008.060665

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None.

    • Funding: Funding for this study was obtained from an internal R&D funding body of the Leeds Teaching Hospitals Trust who had no further involvement in the study.